Newsroom

DALLAS--(BUSINESS WIRE)--Carrington Coleman has expanded its technology and innovation practices with the addition of attorneys Kate Morris and Russ Pearlman. “Kate and Russ are leaders in the practice of AI, data, and technology law,” said Carrington Coleman Managing Partner Monica Latin. “Their arrival strengthens our ability to help clients across industries navigate rapidly evolving issues in AI governance, privacy, cybersecurity, and technology transactions, reflecting our commitment to st...

LONDON--(BUSINESS WIRE)--  As Agent Bank, please be advised of the following rate determined on: 4/13/2026 Issue ¦ Standard Chartered Bank Series - 291 EUR 370,000,000 FRN Due in October 2026     ISIN Number ¦ XS2919743927 ISIN Reference ¦ 291974392 Issue Nomin EUR ¦ 370000000 Period ¦ 4/15/2026 to 7/15/2026   Payment Date 7/15/2026 Number of Days ¦ 91 Rate ¦ 2.604   Denomination EUR ¦ 1000   ¦ 370000000   ¦       Amount Payable per Denomination ¦ 6.58   ¦ 2434600   ¦       Bank of New York    ...

WELLESLEY, Mass.--(BUSINESS WIRE)--Paul M. Wilson and Michael Muldowney, co-hosts of the fourth annual City of Champions Golf Tournament, today announced that their annual event has surpassed $900,000 in cumulative fundraising for prostate cancer research, putting them firmly on the doorstep of the $1 million milestone. This year’s tournament will take place at Wellesley Country Club on Monday, May 11, 2026. Supported by leaders in business and across the community, the tournament benefits orga...

LONDON--(BUSINESS WIRE)--KBRA UK (KBRA) assigns preliminary ratings to seven classes of notes issued by Harvest Funding PLC, a static RMBS securitisation backed by a seasoned non-conforming portfolio of United Kingdom (UK) residential mortgage loans, comprising performing, in-arrears and past-term exposures. The portfolio aggregates to £2.0 billion of first lien loans which are secured by owner occupied (85.8%), buy-to-let (14.1%) and second or holiday homes (0.1%). The seasoning of the portfol...

LONDON--(BUSINESS WIRE)--  As Agent Bank, please be advised of the following rate determined on: 4/15/2026 Issue ¦ Duncan Funding 2024-1 PLC Class - A GBP 500,000,000 FRN Due in July 2071     ISIN Number ¦ XS2793346391 ISIN Reference ¦ 279334639 Issue Nomin GBP ¦ 500000000 Period ¦ 1/22/2026 to 4/22/2026   Payment Date 4/22/2026 Number of Days ¦ 90 Rate ¦ 4.29453   Denomination GBP ¦ 1000   ¦ 500000000   ¦       Amount Payable per Denomination ¦ 10.06   ¦ 5029894.73   ¦       Bank of New York  ...

PARIS--(BUSINESS WIRE)--Regulatory News: Mauna Kea Technologies (Euronext Growth : ALMKT) inventeur de Cellvizio®, la plateforme multidisciplinaire d’endomicroscopie confocale laser par minisonde et par aiguille (p/nCLE), publie aujourd'hui son chiffre d'affaires pour le premier trimestre 2026. Sacha Loiseau, Ph.D., Président-Directeur Général de Mauna Kea Technologies, a déclaré : « Notre performance du premier trimestre 2026 confirme la solide trajectoire de croissance initiée aux États-Unis...

PARIS & BOSTON--(BUSINESS WIRE)--Regulatory News: Mauna Kea Technologies (Euronext Growth: ALMKT), inventor of Cellvizio®, the multidisciplinary probe and needle-based confocal laser endomicroscopy (p/nCLE) platform, today reported its revenue for the first quarter of 2026. Sacha Loiseau, Ph.D., Chairman and CEO of Mauna Kea Technologies, commented: "Our Q1 2026 performance confirms the robust growth trajectory initiated in the U.S. in 2025, which is now expanding internationally. This momentum...

MONTPELLIER, France--(BUSINESS WIRE)--Regulatory News: NFL BIOSCIENCES (Euronext Growth Paris – FR0014003XT0 – ALFNL), société biopharmaceutique développant des médicaments botaniques innovants pour le traitement des addictions, annonce aujourd'hui l’extension de son horizon de trésorerie jusqu’au 3ème trimestre 2027 grâce à un nouveau financement. Bruno LAFONT, Directeur Général et Co-fondateur de NFL Biosciences déclare : « Nous remercions les investisseurs pour leur confiance et leur partici...

MONTPELLIER, France--(BUSINESS WIRE)--Regulatory News: NFL BIOSCIENCES (Euronext Growth Paris – FR0014003XT0 – ALFNL), a biopharmaceutical company developing innovative botanical drugs for the treatment of addictions, today announces the extension of its cash runway until the third quarter of 2027 through new financing. Bruno Lafont, Chief Executive Officer and co-founder of NFL Biosciences, states: “We would like to thank the investors for their confidence and participation in this transaction...

LONDON--(BUSINESS WIRE)--  13-April-2026 Issue: Mitsubishi HC Capital UK Plc Series 959 XS3303163656 Care Amendment Pursuant to our appointment as Agent for the above stated issue, please be advised of the following interest rate determination: Date From: 20-March-2026 Date To: 13-April-2026 Record Date: 10-April-2026 Value Date: 13-April-2026 Benchmark Rate: 3.64818% Margin: 0.43% Total Rate: 4.07818% Floor: 0% Number of Days: 24 Day Count: Actual / 360 Interest Frequency: Quarterly Total Amou...